VIRVir Biotechnology, Inc.
Price
+126%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Vir Biotechnology, Inc. (VIR) reported revenue of $239M in Q2 2026 (quarter ended Jun 30, 2026), up 19583% from the same quarter a year earlier. That came with a gross margin of 100% and net income of $80M (34% of revenue). For the full year FY2025, revenue was $69M (−7.6% year on year) and net income −$438M. Its largest product in Q2 2026 was License And Collaboration at $239M, 100% of the disclosed total, well ahead of Grant at 0.0%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate …Other event · Form 8-K
- Oct 1, 2026On October 1, 2026, Vir Biotechnology, Inc. (the Company) announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 5, 2026 (the Effective Date)Director or officer change · Form 8-K
- Aug 5, 2026Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $238.9MThe company’s own SEC segment disclosure.
- License And Collaboration$238.9M100%
- Grant$11.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.